Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of “Buy” from Brokerages

Annovis Bio, Inc. (NYSE:ANVS) has been assigned an average rating of “Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $37.00.

Separately, D. Boral Capital restated a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th.

Hedge Funds Weigh In On Annovis Bio

Several large investors have recently added to or reduced their stakes in ANVS. JPMorgan Chase & Co. acquired a new stake in shares of Annovis Bio during the 3rd quarter worth approximately $31,000. Two Sigma Investments LP bought a new position in Annovis Bio in the fourth quarter worth $55,000. XTX Topco Ltd acquired a new stake in Annovis Bio during the fourth quarter worth $59,000. Atria Wealth Solutions Inc. bought a new stake in Annovis Bio in the 4th quarter valued at $65,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Annovis Bio in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 15.83% of the company’s stock.

Annovis Bio Stock Performance

Annovis Bio stock opened at $1.86 on Thursday. Annovis Bio has a 52 week low of $1.53 and a 52 week high of $20.00. The firm has a market capitalization of $26.48 million, a PE ratio of -0.42 and a beta of 1.65. The business’s 50-day simple moving average is $2.82 and its 200-day simple moving average is $5.62.

Annovis Bio (NYSE:ANVS) last released its earnings results on Friday, March 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). During the same quarter in the previous year, the business earned ($0.43) earnings per share. Research analysts forecast that Annovis Bio will post -2.19 earnings per share for the current year.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.